AxoGen reports preliminary Q4 revenue $59.9M, consensus $58M

“We are delighted with our preliminary fourth quarter and full year 2025 results. Our strong revenue growth and notable BLA milestone achievement during the quarter further validate our strategic plan and market development strategies, and importantly, Axogen’s (AXGN) ability to operationally execute,” said Michael Dale, President and Chief Executive Officer of Axogen. “The approval of Avance(R) as a biologic therapeutic option for treating peripheral nerve discontinuities combined with our positive momentum across all functions within the business give us confidence that our mission to restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care is progressing as planned.”